BIVI News and Press, BioVie Inc. From 10/25/23

Statistically significant population changes from baseline were observed for all primary and secondary cognitive and functional assessments measured: ADAS-Cog12, ADCS-CGIC, MMSE, CDR, CDR-SB, ADCOMS, and ADL. 1 An apparent significant reduction in amyloid burden from baseline wa...

2023-10-25 10:00:16 ET More on Health Care Select Sector SPDR Health Care Select Sector Fund ETF: Riding The Healthcare Boom Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare (XLV) Stocks to watch in the Health Care sector as earnings close in F...

CARSON CITY, Nev., Oct. 19, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, ...

2023-10-13 13:05:06 ET A national policy that limited the use of a type of brain scan called positron emission tomography (PET) in testing for symptoms of Alzheimer's disease has been removed, the U.S. Centers for Medicare & Medicaid Services (CMS) said on Friday. The cause of the m...

2023-10-13 09:00:58 ET Summary A leaked report by The City University of New York was published yesterday alleging research misconduct by neuroscientist Dr. Hoau-Yan Wang involved in several simufilam-related preclinical publications. Loss of raw research material (a red flag) has...

2023-09-26 12:36:08 ET More on BioVie Seeking Alpha’s Quant Rating on BioVie Inc. Historical earnings data for BioVie Inc. Financial information for BioVie Inc. BioVie: Well-Powered Phase 3 Trial In Alzheimer's Could Greatly Benefit Investors B...

Expects to announce topline data expected in the November/December timeframe. Enrolled patients had underlying medical conditions that are known risk factors for dementia that NE3107 has the potential to improve. CARSON CITY, Nev., Sept. 26, 2023 (GLOBE NEWSWIRE) -- BioVie Inc., (...

CARSON CITY, NV / ACCESSWIRE / September 20, 2023 / As researchers continue to hunt for better treatments for neurodegenerative disease, one of the biggest breakthroughs in decades has been the realization that chronic inflammation may be playing a key role in the onset and progression of debili...

CARSON CITY, Nev., Sept. 19, 2023 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease...

--News Direct-- BioVie chief social impact officer Sarah Hoit joined Steve Darling from Proactive to talk about the growing need for support for individuals suffering from Alzheimer's Disease and their caregivers, including family members. Hoit emphasized that while research into Alzh...